Oculis Holding AG (NASDAQ:OCS) Receives $29.14 Average Price Target from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned an average rating of “Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $29.14.

A number of analysts recently weighed in on the company. Robert W. Baird dropped their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a research report on Tuesday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Tuesday, March 19th. Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research note on Wednesday, March 6th. Finally, HC Wainwright reduced their price objective on Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, April 24th.

Oculis Price Performance

OCS stock opened at $12.37 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29. Oculis has a 1-year low of $9.05 and a 1-year high of $14.50. The company’s 50 day moving average is $11.90 and its 200 day moving average is $11.37.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.28 million. Analysts expect that Oculis will post -1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC purchased a new position in Oculis in the 3rd quarter worth approximately $77,000. Searle & CO. bought a new position in shares of Oculis during the fourth quarter valued at $112,000. Compagnie Lombard Odier SCmA increased its holdings in Oculis by 47.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares in the last quarter. Finally, abrdn plc purchased a new position in Oculis in the 4th quarter worth about $15,980,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.